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Identifyingmarkers of human insulin resistancemay permit
development of new approaches for treatment and pre-
vention of type 2 diabetes. To this end, we analyzed the
fasting plasma metabolome in metabolically characterized
human volunteers across a spectrum of insulin resistance.
We demonstrate that plasma betaine levels are reduced in
insulin-resistant humans and correlate closely with insulin
sensitivity. Moreover, betaine administration to mice with
diet-induced obesity prevents the development of impaired
glucose homeostasis, reduces hepatic lipid accumulation,
increases white adipose oxidative capacity, and enhances
whole-body energy expenditure. In parallel with these
beneficial metabolic effects, betaine supplementation ro-
bustly increased hepatic and circulating fibroblast growth
factor (Fgf)21 levels. Betaine administration failed to im-
prove glucose homeostasis and liver fat content in Fgf212/2
mice, demonstrating that Fgf21 is necessary for betaine’s
beneficial effects. Together, these data indicate that dietary
betaine increases Fgf21 levels to improve metabolic health
in mice and suggest that betaine supplementation merits
further investigation as a supplement for treatment or pre-
vention of type 2 diabetes in humans.
Insulin resistance occurs years before the onset of type 2 di-
abetes and also predicts disease development (1). Fortunately,
both intensive lifestyle programs (exercise, dietary modifica-
tion) and pharmacotherapy are effective for type 2 diabetes
prevention in insulin resistant humans (2). Thus, a key im-
perative is to identify individuals at highest risk to maxi-
mize success and cost-effectiveness of preventive strategies.
Advances in mass spectrometry–based metabolomics
technology have permitted identification of novel meta-
bolic signatures associated with risk for type 2 diabetes
and other components of the metabolic syndrome (3–5).
To identify biomarkers associated with insulin resistance
and type 2 diabetes risk, we analyzed the fasting plasma
metabolome in metabolically phenotyped human volun-
teers. We now report that insulin resistant humans have
reduced plasma levels of N,N,N-trimethylglycine, or gly-
cine betaine (hereafter referred to as betaine). Moreover,
Walford et al. (6) report that plasma betaine levels not
only are associated with reduced incidence of type 2 di-
abetes in a prospective cohort study but also predict suc-
cessful response to prevention strategies.
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Betaine is a modified amino acid found in many foods,
with particularly high content in whole grains (7). Both
betaine intake and plasma levels are inversely correlated
with several metabolic syndrome markers (8,9). Owing to
its dipolar zwitterion structure, betaine functions as a key
intracellular osmolyte. In mammals, betaine metabolism
is dominant in the liver, where it serves as a methyl donor in
the methionine cycle; the enzyme betaine-homocysteine
methyltransferase catalyzes the reaction between beta-
ine and homocysteine, yielding dimethylglycine and methi-
onine (10). Betaine administration decreases homocysteine
levels (11), a cardiovascular risk factor (12), and is used as
treatment for homocysteinemia. Betaine decreases hepatic
lipid content and improves glucose tolerance in rodents
(13–16). However, the molecular mechanisms underlying
these effects remain unknown.
Given the multiple lines of evidence supporting betaine
regulation of metabolism, we tested the impact of betaine
in mice with diet-induced obesity. We demonstrate that
long-term betaine supplementation increases circulating
levels of the systemic metabolic regulator fibroblast growth
factor (Fgf)21, improves glucose homeostasis, reduces
hepatic lipid, and increases whole-body energy expendi-
ture. Betaine fails to improve metabolic health in mice
lacking Fgf21, demonstrating that Fgf21 is required for the
beneficial effects of betaine.
RESEARCH DESIGN AND METHODS
Human Metabolic and Metabolomics Analysis
Protocols were approved by the Joslin Diabetes Center
Committee on Human Subjects, and informed consent
was obtained from all participants. Plasma was obtained
after an overnight fast from 40 healthy individuals with
normal glucose tolerance. Insulin sensitivity was quan-
tified by insulin-modified intravenous glucose tolerance
with minimal-model analysis (17). Mass spectrometry
(Metabolon, Inc.) was used to analyze 193 distinct me-
tabolites. Plasma glucose was measured using glucose
oxidase (2300 Stat Plus, YSI, Yellow Springs, OH) and
insulin by radioimmunoassay (Diagnostic Systems Labora-
tories, Webster, TX).
Animal Experiments
All studies were approved by the Institutional Animal
Care and Use Committee of Joslin Diabetes Center and
the University of Barcelona. Male C57BL/6 mice (Harlan)
were fed chow or a 45% or 60% kcal-from-fat diet (D12450B,
D12451, and D12492, respectively; Research Diets) for
16 weeks. Betaine (Sigma-Aldrich) was administered in
water (1% wt/vol) 1 week prior to starting high-fat feed-
ing and was maintained throughout. Fgf212/2 mice (18)
had been backcrossed with C57BL/6 mice for .10 genera-
tions and were treated using the same protocol and 45% fat
diet.
Metabolic Analysis
Glucose (1.5 g/kg i.p.) and insulin (0.75 units/kg i.p.)
tolerance tests were performed after overnight and 4-h fasts,
respectively. Mice were fasted overnight and anesthetized
prior to sacrifice. Hyperinsulinemic-euglycemic clamps were
performed at the Mouse Metabolic Phenotyping Core,
University of Massachusetts. After overnight fasting, a
primed (150 mU/kg) continuous (15 pmol/kg/min) infusion
of human insulin was initiated, together with 20% glucose
at variable rates to maintain basal glucose. Insulin-stimulated
glucose uptake was normalized to plasma insulin at the
end of the 2-h clamp. Plasma insulin and Fgf21 were
determined by ELISA (Crystal Chem and Millipore, respec-
tively). Plasma betaine was quantified by liquid chromatog-
raphy–mass spectrometry (LC-MS) after fractionation using
an Acquity UPLC BEH HILIC column (Waters) and detec-
tion with a QqQ/MS 6490 mass spectrometer (Agilent).
Betaine content of diets was quantified in methanol extracts
using LC-MS (4000 QTRAP; AB Sciex). d9-betaine (C/D/N
Isotopes) or 13C2-betaine was used as internal standards
for absolute quantification for plasma and chow, respec-
tively. For 60% mouse high-fat diet studies, plasma and
liver metabolites were analyzed by LC-MS (19). Liver
betaine, S-adenosylmethionine, S-adenosylhomocysteine,
methionine, and choline were quantified using stable-isotope
dilution liquid chromatography–electrospray ionization
tandem mass spectrometry (Baylor Research Institute,
Dallas, TX) (20). Hepatic lipid was quantified in chloroform-
methanol extracts (50 mg) using a Triglyceride Assay kit
(Sigma-Aldrich).
Gene Expression
Total RNA was isolated with TRI Reagent (Sigma-Aldrich).
cDNA was synthesized using a high-capacity cDNA kit
(Applied Biosystems) and analyzed by real-time PCR using
SYBR Green (Promega). Oligo sequences can be provided
upon request.
Energy Expenditure
Mice were placed in individual chambers (Oxymax OPTO-
M3 system; Columbus Instruments) with ad libitum access
to food and water. After 24-h adaptation, O2 consumption,
CO2 production, and activity were measured.
High-Resolution Respirometry
Mitochondrial function was assessed in freshly isolated
tissue using high-resolution respirometry (Oxygraph-2k,
Oroboros Instruments, Innsbruck, Austria) (21). Inguinal
white adipose tissue (iWAT) was mechanically permeabilized
(Shredder SG3, PBI Pressure BioSciences, Inc.) in respirom-
etry medium (0.5 mmol/L EGTA, 3 mmol/L MgCl2, 60
mmol/L K-lactobionate, 20 mmol/L taurine, 10 mmol/L
KH2PO4, 20 mmol/L HEPES, 110 mmol/L sucrose, and
0.1% (wt/vol) BSA, pH 7.1). Oxygen flux was measured
by adding malate (final 2 mmol/L), glutamate (10 mmol/L),
and ADP (5 mmol/L) for complex I (CI) or succinate (10
mmol/L) for combined CI+II activity. Subsequently, oligo-
mycin A (2 mg/mL) was added to inhibit ATP synthase
(leak-dependent respiration). Finally, electron transport–
independent flux was assessed after sequential addition
of rotenone (0.1 mmol/L) and anti–mycin A (2.4 mmol/L)
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and subtracted from values of each previous step. Values
are expressed relative to protein.
Histological Analysis
Tissues were fixed, paraffin embedded, and stained with
hematoxylin-eosin or Oil Red O (liver). For the pancreas,
three nonconsecutive sections were labeled with anti-
insulin (Dako) and anti-glucagon IgG (Sigma-Aldrich) and
detected with Cy3- and Cy2-conjugated secondary antibodies
(Jackson ImmunoResearch). Area of islets and adipocytes was
measured in 30 images from three sections per animal using
ImageJ by a blinded investigator.
Primary Hepatocytes
Primary hepatocytes were isolated from C57BL/6 mice
after liver perfusion with collagenase and cultured over-
night in gelatin-coated plates containing DMEM (Sigma-
Aldrich), 10% FBS, and 1 mmol/L insulin and subsequently
incubated with betaine.
Statistical Analysis
All data are presented as mean 6 SEM. Between-group
differences were analyzed using GraphPad Prism, using
two-tailed t test or one-way ANOVA and a post hoc Tukey
honestly significant difference test. Where stated, data
were analyzed by two-way ANOVA with a post hoc
Holm-Sidak test. Metabolomic data were log transformed
and analyzed using R software (www.r-project.org); asso-
ciation with log insulin sensitivity index (SI) was tested
using Pearson correlation. P values were corrected for mul-
tiple comparisons using false discovery rate (www.jstor
.org/stable/2346101). P , 0.05 was considered significant
for all analyses.
RESULTS
Plasma Betaine Is Associated With Insulin Sensitivity
in Humans
The plasma metabolome was analyzed in the fasting state
from individuals across a spectrum of insulin sensitivity
in order to evaluate the impact of insulin resistance. All
participants underwent intravenous glucose tolerance tests
to quantify insulin sensitivity (SI) (22) (range 0.49–14.28).
Participants were categorized as insulin sensitive (IS) or
resistant (IR) based on SI values above or below the median
value of 4.78 for a larger population of normoglycemic
individuals studied at the Joslin Diabetes Center (17). IR
individuals had higher fasting plasma glucose and insulin
levels (Table 1).
We performed unbiased analysis of plasma metabolo-
mics using mass spectroscopy and assessed correlation
with insulin sensitivity (logSI) to identify early signatures
of insulin resistance (Supplementary Data Table 2). The
metabolite with the highest correlation coefficient was
betaine (r = 0.55, P , 0.0005) (Fig. 1A). Betaine concen-
trations were also significantly lower in IR compared with
IS individuals (14% reduction, P , 0.01) (Fig. 1B). Given
the importance of betaine for maintenance of the methio-
nine cycle and systemic metabolism, we hypothesized that
reductions in plasma betaine could contribute to metabolic
defects associated with insulin resistance. We thus deter-
mined the impact of betaine supplementation on in vivo
metabolism in mice with diet-induced obesity.
Betaine Supplementation Improves Glucose
Homeostasis
Male C57BL/6 mice were fed chow (10% kcal from fat)
(LF) or a matched moderate high-fat diet (45% kcal from
fat [HF]) for 16 weeks; high-fat–fed mice were unsupple-
mented or treated with 1% betaine in water (HF and
HF-B, respectively). As expected, high-fat feeding led to
greater weight gain, fasting hyperglycemia, and hyperin-
sulinemia (Table 2). Betaine levels were 50% lower in mice
made insulin resistant with high-fat feeding (Table 2), con-
sistent with lower levels in insulin-resistant humans. Lower
betaine levels in high-fat–fed mice cannot be attributed to
dietary betaine content, as measured betaine content (per
gram) is 19% higher in the high-fat diet and calculated
daily betaine intake is similar for both groups (Supplemen-
tary Fig. 1). Supplementation increased betaine levels by
2.6- and 6.5-fold compared with LF and HF groups (Table
2), respectively, and induced a small decrease in body
weight versus HF mice (Fig. 2A). Consistent with previous
data (15,16), betaine-treated mice had lower fasting insulin
(Table 2) and improved glucose tolerance (Fig. 2B); plasma
insulin was significantly lower in HF-B mice after intraper-
itoneal glucose (Fig. 2C). Insulin tolerance was also improved
Table 1—Clinical characteristics of human participants
IS IR
Subjects, n (female/male) 18 (10/8) 23 (13/10)
Age (years) 35.7 6 2.3 39.4 6 2.5
BMI (kg/m2) 25.8 6 1.0 28.0 6 1.2
Fasting glucose (mg/dL) 87.9 6 1.4 92.9 6 1.8*
Fasting insulin (mU/mL) 4.74 6 0.42 9.87 6 1.55**
SI (IVGTT) 8.12 6 0.6 2.80 6 0.3**
Data are summarized as mean 6 SEM unless otherwise indi-
cated. Metabolic characteristics of study cohort. IVGTT, intra-
venous glucose tolerance test. *P , 0.05; **P , 0.0005.
Figure 1—Plasma betaine levels are associated with insulin sensi-
tivity. A: Correlation of plasma betaine levels with logSI in humans.
B: Categorical analysis (IR vs. IS) of betaine levels. Data are nor-
malized to median values for IS subjects and presented as mean 6
SEM in the categorical analyses. t test **P < 0.01.
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(Fig. 2D). Pancreatic b-cell area was lower in HF-B versus HF
(Fig. 2E), indicating that betaine normalized the b-cell ex-
pansion with high-fat feeding.
We observed similar results in an independent cohort fed
a higher fat diet (60% kcal from fat); betaine supplemen-
tation resulted in reduced body weight and leptin, 50%
reduction in both fasted and refed insulin, and improved
glucose tolerance (Supplementary Fig. 2A–F). Moreover,
insulin sensitivity was improved, as assessed by insulin toler-
ance testing, and there was a trend toward a higher glu-
cose infusion rate during hyperinsulinemic-euglycemic clamp
(2.1-fold; 5.40 6 1.36 vs. 2.53 6 0.76 mg/kg/min/ng/ml,
P = 0.08) (Supplementary Fig. 2G and H).
Indirect calorimetry was performed to assess betaine
effects on energy homeostasis. Betaine administration
increased oxygen consumption by 10% (P , 0.05) in both
light and dark cycles (Fig. 2F). Physical activity did not
differ (Supplementary Fig. 3A), while respiratory exchange
ratio tended to increase in HF-B (P = 0.056) (Supplemen-
tary Fig. 3B). Together with the human data, these obser-
vations prompted us to investigate molecular mechanisms
mediating betaine action, focusing on HF and HF-B groups.
Betaine Reduces Hepatic Triglyceride Content
Since the liver plays a major role in betaine metabolism,
we analyzed betaine effects in this tissue. Supplementa-
tion had no major impact in phosphorylated Akt in
fasted/refed conditions (Supplementary Fig. 4); however,
consistent with previous rodent studies (13–16), betaine
decreased liver weight and triglyceride (TAG) content in
mice fed either 45% (Fig. 3A and B) or 60% fat diets (Sup-
plementary Fig. 5A and B). Fasting plasma TAG levels were
also reduced (Fig. 3C). Given these robust reductions in
hepatic lipid, we used LC-MS to quantify key one-carbon
pathway metabolites in liver from 60% fat-fed mice. Hepatic
betaine, S-adenosylmethionine, and S-adenosylhomocysteine
levels were increased in betaine-supplemented mice (Supple-
mentary Fig. 5C); methionine, homocysteine, choline, and
cystathionine were not significantly altered.
We next examined potential transcriptional contribu-
tions to improved lipid content. Quantitative RT-PCR
revealed no major changes in genes regulating lipogenesis
or lipid oxidation or in one-carbon metabolic pathway
enzymes (Supplementary Fig. 5D). However, expression
of proinflammatory genes Ccl2, Tnfa, Saa2, and Tlr4
(full gene names in Supplementary Table 1) was consis-
tently downregulated in betaine-treated mice (Fig. 3D).
Since betaine has antioxidant properties (23,24), we
assessed tissue oxidative stress by measuring the ratio
of oxidized to reduced glutathione. Betaine supplementa-
tion decreased the oxidized-to-reduced glutathione ratio
by 20% (P , 0.05, Supplementary Fig. 5E), suggesting
reduced oxidative stress.
Betaine Increases Hepatic and Circulating Fgf21
Levels
Given the robust effect of betaine supplementation on
both liver and whole-body metabolism, we hypothesized
that a hepatokine was mediating betaine effects. We
measured hepatokines known to impact glucose homeo-
stasis and energy expenditure, including Angptl3, Angptl4,
Angptl6, Enho, Hgf, Igf1, Sepp1, and Fgf21. Among these,
only Fgf21 mRNA was increased (1.6-fold, P , 0.05) after
betaine treatment (Fig. 3E). Circulating Fgf21 levels were
also increased in HF-B mice (Fig. 3F). For determination of
whether increased liver Fgf21 expression was due to a di-
rect transcriptional effect, primary hepatocytes were incu-
bated with betaine (5–25 mmol/L for 5–24 h). Expression
of Fgf21 was not increased in any of these conditions (Fig.
3G and H), despite increases in Fgf21 in response to tuni-
camycin, a known activator of Fgf21 expression (positive
control for these experiments) (Fig. 3H). Thus, it is unlikely
that effects of betaine on Fgf21 are acute and/or direct.
Since Fgf21 is also expressed in extrahepatic tissues, in-
cluding WAT and brown adipose tissue (BAT), we tested
whether betaine modulated Fgf21 expression in these tis-
sues. We found no differences in expression of Fgf21 or
its receptor Fgfr1 in either tissue (Supplementary Fig. 6).
By contrast, expression of the coreceptor b-klotho was
elevated in iWAT (Supplementary Fig. 6), suggesting
a potential increase in Fgf21 signaling with betaine
supplementation.
Betaine Increases White Adipose Mitochondrial
Oxidative Capacity
Circulating Fgf21 exerts most of its whole-body effects via
adipose tissue (25–27) and induces a browning program
in WAT (28), prompting us to investigate betaine effects
on subcutaneous iWAT. Histological analysis showed a
shift in adipocyte distribution toward smaller size, with
25% decrease (P , 0.05) in mean cell size in HF-B mice
(Fig. 4A). mRNA expression of Ucp1 and Ppargc1a was
increased by 3.9- and 1.5-fold, respectively (P , 0.05
for both), with betaine (Fig. 4B), but expression of the
additional browning markers Cidea or Prdm16 did not
differ. Betaine did not alter Ucp1 or Ppargc1a in BAT or
epididymal WAT (eWAT) (Fig. 4C), indicating that this
Table 2—Body weight gain during the experiment,




gain (g) 9.9 6 0.6a 18.3 6 0.8b 16.6 6 0.7b
Food intake
(kcal/mouse) ND 1,106 6 17 1,100 6 57
Glucose (mg/dL) 74 6 3a 114 6 5b 102 6 4.4b
Insulin (mU/mL) 10.5 6 2.6a 33.6 6 2.9b 21.9 6 1.9c
Betaine (mmol/L) 13.4 6 1.6a 5.3 6 0.8a 35.0 6 5.2b
Data are mean 6 SEM from n = 20 for HF and HF-B and n = 15
for LF from two independent cohorts (n = 10 per group for
betaine levels). Different letters indicate statistically significant
differences between groups, as assessed by one-way ANOVA
and post hoc Tukey honestly significant difference test (P, 0.05).
ND, nondetermined.
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effect was specific for iWAT. Decreased adipocyte cell size
and increased oxidative gene expression together sug-
gested that betaine improved oxidative metabolism in
iWAT. Consistent with this hypothesis and increased in
vivo oxygen consumption, HF-B mice showed enhanced
mitochondrial oxidative capacity in iWAT. Specifically,
we observed increases in oxygen consumption by 1.5-
fold (P , 0.05) after the addition of substrates for both
C1 (malate and glutamate) and CII (succinate) and in leak-
dependent respiration (Fig. 4D).
Absence of Fgf21 Abolishes the Beneficial Metabolic
Effects of Betaine Supplementation
Betaine-induced improvements in glucose homeosta-
sis, hepatic lipid accumulation, energy expenditure, and
iWAT size and oxidative profile are all consistent with
a potential role of Fgf21 in mediating betaine effects.
To test this hypothesis, we investigated the impact of
betaine supplementation in mice null for the Fgf21 gene
(Fgf212/2). Male Fgf212/2 mice were fed 45% kcal from
fat either without or with 1% betaine in water for 16 weeks
Figure 2—Betaine improves whole-body glucose homeostasis and energy expenditure. Mice were fed the LF, HF, or HF-B diet for 16 weeks.
A: Body weight at sacrifice. B: Glucose tolerance test. Insulin levels before and 15 min after intraperitoneal glucose administration (C) and
insulin tolerance test (D) (n = 16 for HF/HF-B; n = 10 for LF). E: b-Cell area was analyzed by immunohistochemistry (n = 8 for HF/HF-B, n = 3 for
LF). F: O2 consumption was monitored in metabolic chambers at week 10 after starting high-fat feeding; data are summarized as light and
dark cycles (gray rectangle) (n = 7 for HF/HF-B). Data are mean 6 SEM. Different letters indicate statistical significance (P < 0.05) between
groups after one-way ANOVA and post hoc Tukey honestly significant difference test: P < 0.05. Different symbols indicate statistical
significance (P < 0.05) after two-way ANOVA and post hoc Holm-Sidak test: &HF vs. LF, #HF-B vs. HF, $HF-B vs. LF.
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(KO and KO-B, respectively). Supplementation increased
plasma levels by fivefold in KO mice (Fig. 5A). Unex-
pectedly, betaine administration to Fgf212/2 mice led
to higher body weight (Fig. 5B) with no difference in
food intake (Fig. 5C); these mice also showed increased
fasting glucose and numerically higher insulin levels
(Fig. 5D and E). Neither glucose nor insulin tolerance
was improved in KO-B vs. KO (Fig. 5F and G). Further-
more, betaine failed to decrease liver weight, TAG con-
tent (Fig. 5H and I), or inflammatory markers in KO mice
(Supplementary Fig. 7). We next analyzed the ef-
fects of betaine in iWAT from Fgf212/2 mice. As shown
in Fig. 5J, betaine treatment did not increase expression
of Ucp1 or Ppargc1a in iWAT from KO-B versus KO mice.
Finally, mitochondrial respiration did not differ between
groups (Fig. 5K). Together, these data indicate that
Fgf21 is necessary for the beneficial effects of betaine
to improve glucose homeostasis, reduce liver TAG accu-
mulation, and improve oxidative metabolism in adipose
tissue.
DISCUSSION
Betaine is the top-ranking plasma metabolite correlated
with insulin sensitivity (SI) in humans with normal glucose
Figure 3—Betaine increases hepatic and circulating Fgf21 levels. A and B: Liver weight (as % of body weight) and hepatic TAG levels were
measured in HF and HF-B mice (n = 20 from two independent cohorts). C: Fasting plasma TAG levels were analyzed. D and E: Hepatic
mRNA levels of inflammatory genes and hepatokines were analyzed by RT-PCR (n = 12 from two independent cohorts). F: Circulating
fasting plasma Fgf21 levels were measured (n = 8). Fgf21 mRNA levels were determined from primary hepatocytes incubated with 10 mmol/L
betaine (Bet) for the indicated times (G) or with the indicated betaine concentrations for 10 h (H); where indicated, hepatocytes were incubated
with DMSO (C) or 5 mmol/L tunicamycin (Tu) for 4 h before Fgf21 mRNA levels were analyzed (n = 2 independent experiments performed in
triplicate). Data are mean 6 SEM. t test *P < 0.05, **P < 0.01. Prot, protein.
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tolerance, as revealed by unbiased metabolomics analysis.
Moreover, increasing betaine levels via long-term dietary
supplementation improve systemic metabolism in mice,
with prevention of impaired glucose homeostasis and liver
fat accumulation, improved insulin sensitivity, increased
energy expenditure, and increased oxidative capacity of
iWAT, even in mice made obese and insulin resistant
with continued high-fat feeding. Thus, plasma betaine con-
centrations can serve as a biomarker of insulin resistance
and a target for prevention and treatment.
More broadly, our data provide support for the emerging
concept that one-carbon metabolic pathways may con-
tribute to the pathogenesis of insulin resistance, type 2
diabetes, and related metabolic disease. Prior cross-sectional
analysis of data from Framingham Heart Study participants
demonstrated inverse correlations between plasma betaine
and several phenotypes associated with metabolic disease,
including BMI, insulin, blood pressure, and lipids (29). De-
ficiency of the betaine metabolite dimethylglycine has
also been recently associated with higher plasma glucose
(30). In new longitudinal prospective studies of Diabetes
Prevention Program (DPP) participants, Walford et al. (6)
report that higher baseline plasma betaine levels are also
associated with a significant reduction in incident diabetes
for up to 10 years. Moreover, plasma betaine levels are
increased with lifestyle intervention, and increases in be-
taine predict the success of these interventions to reduce
diabetes incidence.
Figure 4—Betaine increases iWAT mitochondrial oxidative capacity. A: Adipocyte size was determined in iWAT from HF and HF-B (n = 5)
mice; a representative image, cell size distribution, and group means are shown. B: iWAT mRNA levels were measured (n = 13–14 from two
independent cohorts). C: BAT and eWAT mRNA were analyzed (n = 6). D: Mitochondrial respiratory capacity was measured in permea-
bilized iWAT (n = 8). Data are mean 6 SEM. t test *P < 0.05. Prot, protein.
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While we do not fully understand the mechanisms
responsible for these interesting relationships, reduced
betaine levels in insulin-resistant humans could reflect
reduced intake of betaine-rich foods, as suggested by prior
dietary studies (8,31). However, our findings of reduced
betaine levels in mice fed a defined high-fat diet, de-
spite similar betaine intake, indicate additional mecha-
nisms. Alterations in intestinal absorption, metabolism of
choline-related metabolites by intestinal microbiota (32,33),
or osmotic dilution or increased losses could also contribute
to reduced plasma betaine in insulin resistance. Additional
complexity arises from genetic variation within this path-
way, as evidenced by the recently described relationship
between variation at the dimethylglycine dehydrogenase
(DMGDH) locus, insulin resistance, and incident diabetes
(30). Additional studies will be required to clarify the rela-
tive importance of each of these mechanisms as contribu-
tors to reduced betaine levels in human insulin resistance.
Our results support the efficacy of betaine dietary
supplementation to improve systemic metabolism. Me-
tabolites from the one-carbon metabolism pathway, in-
cluding choline, methionine, folic acid, and betaine, singly
or in combination, have been used to prevent and treat
fatty liver in rodents (15,16,34,35). Our results demon-
strate that betaine also yields beneficial effects in nonhe-
patic tissues, with increases in systemic energy expenditure
and enhanced oxidative metabolism in subcutaneous WAT.
Thus, both hepatic and extrahepatic mechanisms may con-
tribute to betaine-mediated improvements in insulin sen-
sitivity and glucose tolerance.
Figure 5—Lack of Fgf21 abolishes betaine’s metabolic effects. Fgf212/2 mice were fed a high-fat diet either with no supplement (KO) or
with 1% betaine (KO-B). A–E: Plasma betaine, body weight, food intake, and fasting plasma glucose and insulin were measured. F and G:
Glucose and insulin tolerance was determined. H and I: Liver weight (as % of body weight) and liver TAG content were measured. J: iWAT
mRNA levels of indicated genes were determined. K: Mitochondrial respiratory capacity was measured in permeabilized iWAT. Data are
mean 6 SEM. n = 6–7 mice per group. t test *P < 0.05. AUC, area under the curve. Prot, protein.
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One potential mediator of betaine-induced improve-
ments in systemic metabolism is the hormone Fgf21.
Fgf21 regulates whole-body glucose and lipid metabolism
and is under investigation as a novel metabolic dis-
ease therapeutic (36,37). Plasma Fgf21 is elevated during
fasting and in response to low protein intake via Perox-
isome proliferator-activated receptor alpha (PPARA) and
general control nonderepressible 2-dependent regulation
(38,39); Fgf21 is also increased in obesity and nonalco-
holic fatty liver disease and correlates with hepatic fat,
suggesting the possibility of resistance to hormone ac-
tion (38,40–42). Further increases in Fgf21 in rodents
via transgenic overexpression or injection of recombi-
nant Fgf21 improve glucose homeostasis, decrease
hepatic lipid, increase whole-body energy expenditure,
and reduce body weight (43–45). This is of particular
relevance, as our results demonstrate that long-term be-
taine supplementation yields a more modest increase in
both hepatic and circulating Fgf21 by 1.6-fold, while
reducing hepatic TAG content. We do not fully under-
stand the mechanisms responsible for betaine-mediated
increases in Fgf21 expression or secretion. Our experi-
ments in primary hepatocytes indicate that betaine-
induced increases in Fgf21 expression are likely not to be
acute or direct but, rather, indirectly mediated by im-
provements in hepatic insulin action, transcriptional ef-
fects on PPARA or related nuclear receptor complexes
(38,39,46,47), reduced lipid accumulation, or reduced
oxidative stress or via extrahepatic metabolic effects.
Fgf21-induced browning in subcutaneous WAT (28)
could contribute to enhanced energy expenditure. Consis-
tent with this effect, betaine treatment increased expres-
sion of genes regulating oxidative metabolism, including
Ucp1 and Ppargc1a, in subcutaneous WAT; other brown-
ing markers were not modified. In parallel, high-resolution
respirometry revealed increased iWAT mitochondrial oxi-
dative capacity in betaine-treated mice. While we do not
fully understand the mechanisms mediating this ef-
fect, increased mitochondrial oxygen consumption and
leak-dependent respiration could be mediated in part by
the modestly increased Ucp1 and Ppargc1a expression in
betaine-treated adipose. Effects of Fgf21 have recently
been shown to be Ucp1 independent (48,49), suggesting
important contributions of Ppargc1a and other regulators
of oxidative metabolism (48,50). Expression of Ucp1 and
Ppargc1a did not change with betaine in either BAT or
eWAT, consistent with greater susceptibility of iWAT to
browning stimuli (51) and Fgf21-mediated induction of
thermogenic programs (28). Although we cannot rule out
a direct effect of betaine in eWAT (16), the absence of Ucp1
or Ppargc1a induction in iWAT from betaine-treated
Fgf212/2 mice indicates that Fgf21 is necessary for long-
term betaine effects.
Improvements in whole-body glucose homeostasis, liver
fat, energy expenditure, and iWAT are all consistent
with Fgf21 as a mediator of betaine action. Indeed, beta-
ine supplementation failed to improve metabolic health in
Fgf212/2 mice, demonstrating that Fgf21 is necessary for
betaine metabolic effects. Liver-derived Fgf21 is considered
the main source of circulating Fgf21 and responsible for its
beneficial systemic effects (40); betaine-induced increases
in hepatic Fgf21 mRNA paralleled increased plasma levels.
However, we recognize that these mice bear a whole-body
knockout, and thus we cannot fully exclude a potential role
for extrahepatic Fgf21. Unexpectedly, betaine administra-
tion to Fgf212/2 mice led to worsening of some meta-
bolic parameters. A plausible explanation is that betaine
demethylation ultimately yields glycine, which can be oxi-
dized and provide additional calories. Thus, long-term supple-
mentation could contribute to higher cumulative calorie
intake; lack of Fgf21 might impede expenditure of these
extra calories, worsening metabolic health. Another possi-
bility is that Fgf21 could regulate betaine metabolism and
function; lack of Fgf21 would impede the beneficial effects
exerted by long-term betaine supplementation by altering
its metabolism.
Additional mechanisms are likely to contribute to
betaine-induced improvements in systemic and hepatic
metabolism. Betaine is a crucial methyl group donor in
the methionine cycle, converting homocysteine into methi-
onine and dimethylglycine in a reaction catalyzed by the
enzyme Bhmt. Methionine is sequentially converted into
S-adenosylmethionine, and dimethylglycine is further
metabolized via the dimethylglycine dehydrogenase to
glycine. It is interesting that betaine supplementation
increased hepatic content not only of its direct product
dimethylglycine, but also of S-adenosylmethionine and
its demethylation product S-adenosylhomocysteine (52).
Thus, while static assessment of the metabolome does
not allow assessment of net cycle flux, these and other
downstream metabolites of betaine may be important
modulators of betaine effects.
Results from Bhmt2/2 mice indicate additional complex-
ity (53). These mice show increased liver fat, possibly due
to impaired methionine cycle activity and phosphatidylcho-
line biosynthesis. Surprisingly, Bhmt2/2 mice are leaner
and have improved glucose homeostasis, increased energy
expenditure, and higher respiratory exchange ratio, resem-
bling the phenotypic responses to betaine. Interestingly,
lack of Bhmt also increases betaine accumulation and cir-
culating Fgf21, strongly supporting a role for betaine itself,
rather than solely its methyl donor capacity, in increas-
ing Fgf21 levels and improving whole-body metabolism.
Further studies will be required to evaluate flux through
one-carbon metabolic pathways and to identify the con-
tribution of specific metabolites to betaine-mediated im-
provements in both hepatic lipid metabolism and Fgf21
secretion.
Another unique feature of betaine is its zwitterion
structure; thus, osmolyte functions may also contribute to
betaine-mediated improvements in metabolic health. Fi-
nally, betaine may also reduce oxidative stress, as demon-
strated in multiple tissues and experimental paradigms
(23,24), potentially related to betaine-mediated increases
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in glutathione biosynthesis and antioxidant responses.
In agreement, we found that betaine reduces the ratio
of oxidized/reduced glutathione. Reductions in oxidative
stress may also be linked to increased complete fatty acid
oxidation and AMP kinase activation, as observed with a
variety of methyl donors (13,35,54).
The robust effects of betaine supplementation in
rodents have prompted human clinical studies focusing
on fatty liver and weight loss. Betaine administration to
obese humans with nonalcoholic fatty liver disease pro-
tected against worsening steatosis and improved hepatic
inflammation but did not fully reverse disease (55). In
another study, betaine administration to obese individuals
on a hypocaloric diet did not enhance weight loss (56).
However, these studies were performed on subjects with
a preexisting condition and were not designed to examine
glucose homeostasis. By contrast, new human data, pre-
sented by Walford et al. (6), indicate that betaine levels
are not only linked to diabetes risk but also increased in
response to lifestyle interventions that successfully reduce
diabetes incidence.
Taken together, our human and animal model data
support a potential use for long-term betaine supplemen-
tation as part of a comprehensive lifestyle intervention
aimed at metabolic disease prevention. Future clinical
studies will be required to establish whether increased
intake of betaine-rich foods and/or long-term betaine
supplementation will be a safe and effective strategy to
improve metabolic health and prevent type 2 diabetes in
at-risk humans.
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